Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country
Choose language: English

Mostly false Scientifically refuted Certainty of evidence: moderate provisional C-PPI-09

Acid blockers are 'deadly poison' that cause cancers, autoimmune diseases, infertility, erectile dysfunction, depression, fatty liver and irritable bowel; their spread since about 2004–2005 explains a doubling of cancer and erectile dysfunction.

Safety note: Do not stop a prescribed PPI on the basis of a diet without medical review. Stopping a PPI that was prescribed to prevent bleeding (e.g. with aspirin plus clopidogrel, anticoagulants or NSAIDs in people at high risk, or after a bleeding ulcer), or for Barrett's oesophagus, severe erosive oesophagitis (LA grade C/D), an oesophageal ulcer or a peptic stricture (including after dilatation), can lead to serious gastrointestinal bleeding or complications; guidelines (AGA 2022 BPA 4-7, ACG 2022, NICE CG184) say these patients should generally not discontinue PPIs. The medically accepted position is to review the indication regularly with a doctor and to de-prescribe only when no indication remains, warning about a few weeks of rebound symptoms. Alarm symptoms (vomiting blood, black stools, difficulty swallowing, unintended weight loss, anaemia, or new reflux/indigestion with weight loss at age 55 or over) need prompt medical assessment (NICE NG12).
In short: This claim is mostly false: there is a small, uncertain signal for stomach cancer with long-term PPI use (about 1 extra case per 1,200-2,100 users over 5-10 years in one study), but no good evidence that PPIs cause the other listed diseases, and calling them deadly poison or blaming them for rising disease rates is not supported. Stopping a PPI that protects against bleeding can be dangerous.
Conclusion: Mostly false: apart from a small, uncertain stomach cancer signal, the listed harms are not supported, and 'deadly poison' is wrong.
  1. Original statement
  2. Scientific assessment
  3. Scientific evidence in detail
  4. In plain language
  5. Studies on this claim
  6. Regional context
  7. What applies in my country?
  8. References

Original statement

خد يا بتاع الجهاز الهضمي اعرف ان مثبطات الحموضه بتجيب امراض مناعيه وسرطان وعقم وارتخى عند الرجاله >> واكتئاب | بص مثبطات الحموضه يا عبد الله في حد ذاتها سم قاتل يعني طالما مثبطات الحموضه بقت موجوده ا اعرف ا ان انت ا المرض جالك حرفيا مناعتك وقعت الام ضهرك ظهرت شعرك وقع عجزت ا عضمك اتاكل اا انسولينك طلع بالرغم ان ان انت ما بتاكلش اصلا هتتخن هتربي كرش

verbatim according to source. Translation by the project; the Arabic wording is authoritative.

Translation

Acid blockers are 'deadly poison' that cause cancers, autoimmune diseases, infertility, erectile dysfunction, depression, fatty liver and irritable bowel; their spread since about 2004–2005 explains a doubling of cancer and erectile dysfunction.

Origin

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
اتفرجوا عالبودكاست ده وقولولي رأيكوا عشان انزلكوا الحلقه التانيه منه (Open source)
Published
9 April 2026
Timestamp
not available (transcript has no timings)
Attribution uncertainty
Podcast/live-stream machine transcript. In 6T7S4CEKswY the word 'depression' follows a speaker change (>>) and may have been added by the interviewer and affirmed by Elawady. original_ar joins separate verbatim passages with ' | '.
Claimed mechanism

Not specified; general toxicity of acid suppression.

Claimed health effect

Cancer, autoimmune disease, infertility, ED, depression, fatty liver, IBS.

Population concerned

All users.

Geographic restriction by Elawady

none found

Diverging source versions

بص مثبطات الحموضه يا عبد الله في حد ذاتها سم قاتل يعني طالما مثبطات الحموضه بقت موجوده ا اعرف ا ان انت ا المرض جالك حرفيا مناعتك وقعت الام ضهرك ظهرت شعرك وقع عجزت ا عضمك اتاكل اا انسولينك طلع بالرغم ان ان انت ما بتاكلش اصلا هتتخن هتربي كرش

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا لايف حلو (Open source)
Published
29 March 2026
Timestamp
0:11:45 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)

يعني انا كونترلوك قلت عليه بدل المره 1000 مره بيجيب سرطانات وامراض مناعيه

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
زرع الكلي ： الحمد لله مناقشة حرة (Open source)
Published
16 February 2025
Timestamp
0:36:50 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)

انا في 2004 حضرت مثبطات المناعه اللي هي النهارده برشام بقى عادي اللي هو مثبطات الحموضه الكونترولوك والنكسيام والحاجات والبيبلوك والبيبتيوك وكل اللوك ده اللي هو بينزلوها دلوقتي من غير روشته ولا اي حاجه الدوا ده 2004 ما كانش عارف يدخل البلد ولا عارف يمشي فبقوا يجولنا احنا في الرعايه شغلوه بدا وحطوه بدل الزنتاك الزنتاج ده برض حاجه شبهه بس كان اقل فعاليه لان هو ما كانش بيقفل الحمض قوي بس ومع ذلك كانوا يكتبوا في الروشي بتاعته بيجيب اضطرابات هرمونيه ما كانش حد فاهم ليه بياثر على الذكوره بيقلل الرغبه الجنسيه ده فين ده في نشط الزنتان طب ايه اختلاف الزنتاك عن الكونترلاك او عند النكسيم اهو نفس الفكره انا هقفل حمض المعده بقى يبقى الموضوع لازم تربطه لي بحاجه اقول لك لا لا اصل المولكيول ده غير ده اصل الميكانزم ده غير ده يا باشا الاند الاند ريزلت انا بقفل الحمض فسنه 2004 اما تيجي تحسبها دلوقتي 2026 شوف في ال 20 سنه 22 سنه تضاعف حالات السرطان وضعف الانتصاب وسرطانات البروستاتا

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
بودكاست قبل رمضان (Open source)
Published
17 February 2026
Timestamp
0:52:55 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)

مع وجود مثبطات الحموضه التي طرحت في الاصوات يعني في حدود ال عاما من 2005 اطرحت اسواق البي بي ايز بدء من الكونترول الجد فاذر والجاي ورا لا يجب اهمالله ومع وجود تطور للمرض وظهور السرطانات لا يجب تجاهل دور مثبطات الحموضه في ظهور هذه الاعراض

Source status
Video transcript (own words)
Attribution
Elawady (machine transcript)
Video
بيان فلسفه النظريه (Open source)
Published
14 February 2026
Timestamp
0:06:12 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)

أدوية مثبطات الحموضة ممنوعة عندي بشكل دائم — هي سموم تسبب الكبد الدهني والقولون العصبي، وتمنع الجسم من الاستفادة من الطعام وامتصاص الحديد وفيتامين ب12 والمعادن، وتعالج الأعراض فقط بينما تفاقم المشاكل الأساسية من نمو بكتيري وسوء هضم.

Source status
Archive quote (no location given)
Attribution
Elawady (archive paraphrase; source video not given)
Origin
https://eltayebat.com/rule/acid-blockers/

Scientific assessment

Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

Acid blockers are poison and cause cancer, autoimmune disease, infertility, ED, depression, fatty liver and IBS.

2. What is demonstrably correct?

Some cohort studies report associations of long-term PPI use with gastric cancer (Cheung 2018: HR 2.44 after H. pylori eradication; Abrahami 2022: HR 1.45 versus H2 blockers, I-PPI-108) and dementia (Gomm 2016: HR 1.44); PPIs are overused (see C-PPI-11).

3. What is wrong or exaggerated?

'Deadly poison' and the list of diseases are not supported. The gastric cancer signal is small in absolute terms (about 1 extra case per 1,200-2,100 users over 5-10 years in I-PPI-108) and partly explained by protopathic bias (I-PPI-107); the dementia signal was not confirmed by the COMPASS RCT. No evidence was found for infertility (semen quality unaffected, I-PPI-109), erectile dysfunction, depression, fatty liver or autoimmune disease as PPI effects. Rising cancer or ED figures since 2004 are an ecological correlation without causal value.

4. What remains unclear?

Long-term (>10 years) effects on gastric cancer in specific groups remain under study.

5. Which studies support it?

A-PPI-11 (gastric cancer association), A-PPI-04 (dementia association), I-PPI-108 (gastric cancer HR 1.45 vs H2RA, small absolute risk).

6. Which studies contradict it?

COMPASS (I-PPI-01): no significant differences for cancer, dementia and other outcomes except enteric infections. Sawaid 2026 (I-PPI-107): no excess upper GI cancer with long-term use after handling protopathic bias. Keihani 2018 (I-PPI-109): no association with semen quality.

7. What applies to Germany and Europe?

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

8. What is known about Egypt?

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

9. What practical conclusion is appropriate?

Stopping an indicated PPI out of fear of these diseases is not supported by evidence and can be harmful (see C-PPI-10).

Assessment details

Rationale for certainty of evidence

The best active-comparator cohort found a gastric cancer HR of 1.45 versus H2RAs with a very small absolute excess (number needed to harm 2121 at 5 years and 1191 at 10 years; I-PPI-108). A 2026 case-control study showed that upper GI cancer associations are concentrated in the months before diagnosis and disappear after accounting for symptoms that lead to PPI prescriptions (protopathic bias; I-PPI-107). The COMPASS RCT found no excess of cancer or other outcomes except enteric infections over 3 years (I-PPI-01). For infertility, the only identified study found no effect on semen quality (I-PPI-109); for erectile dysfunction, depression, autoimmune disease and fatty liver no adequate evidence was found. Ecological trends since 2004 cannot separate PPIs from ageing, diagnosis and other changes.

Source quality

Video statements; no studies cited by Elawady for these outcomes.

Regional transferability

Not region-specific.

Individual exceptions

None identified.

Regional scope of the claim
general (biological/medical)
Last reviewed
26 October 2026 provisional

Scientific evidence in detail

Scientifically refuted – High-quality evidence shows the opposite, or the claim contradicts well-established physiology.

Research question: Are acid blockers 'deadly poison' that cause cancers, autoimmune diseases, infertility, erectile dysfunction, depression, fatty liver and IBS, explaining rising rates since 2004-2005?

Research question in detail (PECO)
Population
PPI users
Intervention or exposure
PPI use
Comparison
H2RA use / non-use / placebo
Geographic scope
universal pharmacology
Outcomes
  • Cancer (gastric, upper GI)
  • Other listed diseases
  • Mortality

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

What speaks against the claim?

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

Apart from a small, uncertain gastric cancer signal, the listed harms are not supported; 'deadly poison' and an explanation of population-wide disease trends are incompatible with randomised and absolute-risk data.

Why some studies weigh more

RCT and bias-controlled observational data outweigh crude associations; ecological trend arguments have no causal value.

Is a causal relationship established? Not established Gastric cancer: possible small effect; other listed diseases: no evidence identified (infertility contradicted weakly; ED, depression, autoimmune disease, fatty liver: no good studies found).

Remaining uncertainty

Long-term (>10 years) gastric cancer risk in H. pylori-exposed people.

Justified conclusion

Mostly false.

Why do studies seem to disagree?

Abrahami (HR 1.45) vs Sawaid (no excess after handling protopathic bias): differ in comparator (H2RA vs non-users), exposure timing and adjustment for symptom diagnoses.

Does this depend on the country?
General biological effects
Pharmacology of PPIs is the same in Egypt and Europe.
Eating habits
Not decisive.
Origin of the food
Not relevant.
Contaminants
Not relevant (except ranitidine NDMA impurities, C-PPI-08).
National production conditions
Generic products are used in both regions; no evidence of different pharmacological effects.
Legal rules
PPIs are partly available without prescription in Egypt and (small packs, short-term) in the EU; prescribing practices differ.
Actual monitoring data
No Egyptian outcome data identified; one Egypt/Iraq pharmacist survey (I-PPI-120).

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check
  • Absolute excess from NNH – 47 per 100,000 at 5 y; 84 per 100,000 at 10 y recalculated
  • Log-symmetry and protopathic pattern – Recent aOR 4.01 (3.20-5.03) vs remote 0.62 (0.51-0.75) consistent CIs; pattern of reverse causation recalculated
Certainty of the overall evidence (GRADE, simplified)
Main outcome
Cancer and other serious disease caused by PPIs
Starting level
high (randomised trials)
Reasons for downgrading
  • imprecision (3-year RCT)
  • indirectness for long-term cancer
Result
moderate

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Clinical guidelines and official statements checked
  • AGA (American Gastroenterological Association): AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review (Targownik LE et al., Gastroenterology 2022; I-PPI-04) (2022) · Original publication
    Best Practice Advice read verbatim in the PubMed record: regular review and documentation of the indication (BPA 1); trial of de-prescribing for all without a definitive indication (BPA 2); complicated GERD (severe erosive oesophagitis, oesophageal ulcer, peptic stricture) generally not for discontinuation (BPA 4); Barrett's oesophagus, eosinophilic oesophagitis, idiopathic pulmonary fibrosis generally not for de-prescribing (BPA 5); assess upper GI bleeding risk first and do not de-prescribe in high-risk patients (BPA 6-7); warn about transient rebound symptoms (BPA 8); tapering or abrupt stop both possible (BPA 9); decide on indication, not on fear of PPI-associated adverse events (BPA 10). The publisher page could not be fetched (HTTP 403).
  • NICE: Suspected cancer: recognition and referral (NG12), upper GI section (I-GUT-109) (2015, page updated April 2026) · Original publication
    Suspected cancer pathway referral for dysphagia, or age 55+ with weight loss plus upper abdominal pain, reflux or dyspepsia; consider endoscopy for haematemesis and for age 55+ with treatment-resistant dyspepsia or upper abdominal pain with low haemoglobin.
  • ACG (American College of Gastroenterology): ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (Katz PO et al. 2022; I-PPI-10) (2022) · Original publication
    Full text read: weight loss recommended for overweight/obese patients (strong, moderate evidence); avoid meals within 2-3 h of bedtime, avoid tobacco, avoid 'trigger foods', elevate head of bed for nocturnal symptoms (conditional, low evidence); Table 3 rates 'avoid carbonated beverages' as moderate evidence and recommendable; PPIs over H2RAs for healing erosive oesophagitis (strong, high evidence); attempt to discontinue PPIs in patients without erosive oesophagitis or Barrett's whose symptoms resolved (conditional, low); maintenance PPI indefinitely or surgery for LA grade C/D oesophagitis (strong, moderate); endoscopy first for dysphagia or alarm symptoms (weight loss, GI bleeding); rebound shown in healthy controls but strong evidence for symptom increase after abrupt withdrawal in patients is lacking.
Search strategy

Documented literature searches for this review (search strings in the original database syntax).

DatabaseDateSearchLooking forHitsIncluded
Europe PMC26 October 2026TITLE:("proton pump inhibitor*") AND TITLE:"gastric cancer" AND (cohort OR "meta-analysis") AND PUB_YEAR:[2019 TO 2026]supporting evidence14
Europe PMC26 October 2026TITLE:("proton pump inhibitor*") AND TITLE:(cancer) AND ("active comparator" OR "histamine-2" OR "H2RA") AND PUB_YEAR:[2019 TO 2026]both directions11
Europe PMC26 October 2026AUTH:"Abrahami D" AND TITLE:"gastric cancer"supporting evidence1
Europe PMC26 October 2026TITLE:("proton pump inhibitor*") AND TITLE:(depression OR "erectile" OR infertility OR "autoimmune" OR "fatty liver" OR NAFLD OR "semen")supporting evidence15
PubMed (E-utilities esearch)26 October 2026(proton pump inhibitors[mh]) AND (neoplasms[mh] OR depression[mh] OR erectile dysfunction[mh] OR infertility[mh] OR autoimmune diseases[mh]) AND (meta-analysis[pt] OR cohort[tiab]) AND 2020:2026[dp]both directions186
PubMed efetch (record of PMID 35183361)26 October 2026efetch id=35183361 (AGA 2022 de-prescribing BPA statements); publisher page attempted via WebFetch returned HTTP 403guidelines1
Web (curl/WebFetch of guideline page)26 October 2026https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancerguidelines1

Open questions

Data on erectile dysfunction, depression, autoimmune disease and fatty liver with appropriate designs.

How deeply was this checked?

6 linked studies: 2 checked in full text (1 of them with a structured risk-of-bias assessment), 4 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict
  1. 25 October 2026 · Phase 1 · Initial assessment: Mostly false (low)
  2. 26 October 2026 · Phase 4 (systematic evidence review) · Verdict changed: Mostly false (low) → Mostly false (moderate)
    Certainty raised: absolute-risk data from the best active-comparator cohort and a study demonstrating protopathic bias now quantify the cancer signal as small and partly artefactual; with the RCT this gives moderate certainty that the sweeping claim is mostly false.
    New sources: I-PPI-107 I-PPI-108 I-PPI-109

In plain language

Some studies found that long-term acid blocker users more often get stomach cancer, but the extra risk is small (about one extra case among more than a thousand users over many years in one study), and part of it comes from people starting the medicine because of symptoms of a cancer not yet diagnosed. A large randomised trial found no more cancer or dementia over three years. There is no good evidence that PPIs cause infertility, impotence, depression, fatty liver or autoimmune diseases, and calling them deadly poison is not accurate. Stopping a PPI that protects against bleeding can be dangerous.

Studies on this claim

Studies supporting the claim (1)

  • PPIs and stomach cancer after H. pylori treatment

    Cheung KS et al.. Gut 2018 · PMID 29089382 · DOI 10.1136/gutjnl-2017-314605
    Cohort studycited by the Tayebat archiveabstract checked★ key study

    Long-term PPI use was linked to more gastric cancer, about 4 extra cases per 10,000 person-years.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    GC after eradication.

    How was the study done?

    Cohort with propensity scores.

    How many people, animals or samples were studied?

    63,397.

    What was actually found?

    Association, duration gradient.

    How large was the observed effect?

    HR 2.44; ARD 4.29/10,000 py.

    What do the results mean in everyday life?

    Small absolute excess.

    What are the study's limitations?

    Few events; confounding.

    What does it say about Elawady's specific claim?

    Partly supports cancer claim for gastric cancer only.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    Causation; other cancers.

    Scientific details →

Studies contradicting or limiting the claim (3)

  • Pantoprazole safety in a large randomised trial

    Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056
    Randomised controlled trialindependent cross-checkfull text, structured risk-of-bias assessment★ key study

    Over three years, only gut infections were more common with pantoprazole (1.4% vs 1.0%).

    Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Test PPI harms in an RCT.

    How was the study done?

    Placebo-controlled trial.

    How many people, animals or samples were studied?

    17,598 heart/vascular patients.

    What was actually found?

    No excess harm except enteric infections.

    How large was the observed effect?

    OR 1.33 enteric infections.

    What do the results mean in everyday life?

    PPIs are largely safe for 3 years.

    What are the study's limitations?

    3-year duration; specific population.

    What does it say about Elawady's specific claim?

    Contradicts most broad harm claims; supports infection risk.

    Do the results apply to Germany and Europe?

    Applicable.

    What can explicitly not be concluded from this study?

    Very long-term effects.

    Scientific details →

  • PPI-cancer link largely reflects early cancer symptoms

    Sawaid IO et al.. PLoS Med 2026 · PMID 41493925 · DOI 10.1371/journal.pmed.1004842
    Case-control studyindependent cross-checkfull text checked★ key study

    People often start acid blockers because of symptoms of a still-undiagnosed cancer; after accounting for this, long-term PPI use was not linked to more upper GI cancer.

    Cancer association explained by protopathic bias; no excess with long-term use

    Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Re-examine PPIs and upper GI cancer.

    How was the study done?

    Matched case-control, 875 cases.

    How many people, animals or samples were studied?

    Israeli health records, incl. Arab citizens.

    What was actually found?

    Strong recent-use link vanished for earlier use.

    How large was the observed effect?

    aOR 4.01 recent esomeprazole; 0.62 remote omeprazole.

    What do the results mean in everyday life?

    Alarm symptoms should be investigated, not blamed on the medicine.

    What are the study's limitations?

    Observational; OTC use missed.

    What does it say about Elawady's specific claim?

    Contradicts 'PPIs cause cancer'.

    Do the results apply to Germany and Europe?

    Moderately applicable.

    What can explicitly not be concluded from this study?

    Cannot exclude effects after >10 years.

    Scientific details →

  • No link between PPIs and sperm quality

    Keihani S et al.. Asian J Androl 2018 · PMID 28879865 · DOI 10.4103/aja.aja_35_17
    Cohort studyindependent cross-checkabstract checked

    Among men at a fertility clinic, those taking PPIs had similar semen results to men taking no medicines.

    No association of PPI use with semen quality

    Does the study support the specific claim? No · Methodological quality: low · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Check PPIs and semen quality.

    How was the study done?

    Retrospective cohort.

    How many people, animals or samples were studied?

    248 PPI users, 7698 controls.

    What was actually found?

    No significant differences.

    How large was the observed effect?

    Not significant.

    What do the results mean in everyday life?

    No sign that PPIs harm sperm.

    What are the study's limitations?

    Weak design.

    What does it say about Elawady's specific claim?

    Contradicts infertility claim (weakly).

    Do the results apply to Germany and Europe?

    Applicable.

    What can explicitly not be concluded from this study?

    Cannot exclude small effects.

    Scientific details →

Studies with mixed or unclear results (2)

  • PPIs and dementia in German claims data

    Gomm W et al.. JAMA Neurol 2016 · PMID 26882076 · DOI 10.1001/jamaneurol.2015.4791
    Cohort studycited by the Tayebat archiveabstract checked

    Regular PPI users were diagnosed with dementia 1.44 times as often.

    Does the study support the specific claim? Unclear · Methodological quality: low · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Dementia risk with PPIs.

    How was the study done?

    Insurance claims analysis.

    How many people, animals or samples were studied?

    73,679 people ≥75 years.

    What was actually found?

    Association with dementia.

    How large was the observed effect?

    HR 1.44.

    What do the results mean in everyday life?

    Not proof of harm.

    What are the study's limitations?

    Claims data; confounding.

    What does it say about Elawady's specific claim?

    Not directly used by archive.

    Do the results apply to Germany and Europe?

    German data.

    What can explicitly not be concluded from this study?

    Causation.

    Scientific details →

  • Long-term PPI use linked with a small rise in stomach cancer

    Abrahami D et al.. Gut 2022 · PMID 34226290 · DOI 10.1136/gutjnl-2021-325097
    Cohort studyindependent cross-checkabstract checked★ key study

    Compared with H2 blockers, PPI users had a 45% higher relative risk of stomach cancer, but only about 1 extra case per 1,200-2,100 users over 5-10 years.

    Gastric cancer HR 1.45 vs H2RA; absolute excess ~1 per 1000-2000 users

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Compare stomach cancer risk of PPI and H2RA users.

    How was the study done?

    Large UK cohort.

    How many people, animals or samples were studied?

    Over 1.1 million new users.

    What was actually found?

    HR 1.45; dose-response.

    How large was the observed effect?

    NNH 2121 (5 y), 1191 (10 y).

    What do the results mean in everyday life?

    If real, the extra risk is small; use PPIs only when indicated.

    What are the study's limitations?

    Observational; H. pylori not fully known.

    What does it say about Elawady's specific claim?

    Partly supports a cancer concern; contradicts 'deadly poison'.

    Do the results apply to Germany and Europe?

    UK data, applicable to Europe.

    What can explicitly not be concluded from this study?

    Cannot prove causation.

    Scientific details →

Regional context

Germany / EU

PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.

Egypt

Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.

What applies in my country?

General scientific assessment

Mostly false Mostly false: apart from a small, uncertain stomach cancer signal, the listed harms are not supported, and 'deadly poison' is wrong.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study.. Cheung KS et al.. Gut 2018 · PMID 29089382 · DOI 10.1136/gutjnl-2017-314605
  2. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.. Moayyedi P et al.. Gastroenterology 2019 · PMID 31152740 · DOI 10.1053/j.gastro.2019.05.056
  3. Association between proton pump inhibitor use and upper gastrointestinal cancer: A matched case-control study accounting for reverse causation and confounding by indication.. Sawaid IO et al.. PLoS Med 2026 · PMID 41493925 · DOI 10.1371/journal.pmed.1004842
  4. Proton-pump inhibitor use does not affect semen quality in subfertile men.. Keihani S et al.. Asian J Androl 2018 · PMID 28879865 · DOI 10.4103/aja.aja_35_17
  5. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.. Gomm W et al.. JAMA Neurol 2016 · PMID 26882076 · DOI 10.1001/jamaneurol.2015.4791
  6. Proton pump inhibitors and risk of gastric cancer: population-based cohort study.. Abrahami D et al.. Gut 2022 · PMID 34226290 · DOI 10.1136/gutjnl-2021-325097

← Back to overview